March 4, 2020Open Access

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Key Points

Key points are not available for this paper at this time.

Abstract

Monthly injections of long-acting cabotegravir and rilpivirine were noninferior to standard oral therapy for maintaining HIV-1 suppression. Injection-related adverse events were common but only infrequently led to medication withdrawal. (Funded by ViiV Healthcare and Janssen; ATLAS ClinicalTrials.gov number, NCT02951052.).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Swindells et al. (Wed,) studied this question.

synapsesocial.com/papers/69d98eb21ad561c673684944 https://doi.org/https://doi.org/10.1056/nejmoa1904398

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection2020 · 463 citations
2Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients2012 · 158 citations
3Drug safety assessment in clinical trials: methodological challenges and opportunities2012 · 224 citations
4Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral‐naïve, HIV‐1‐infected patients in ECHO and THRIVE2010 · 22 citations
5World Medical Association Declaration of Helsinki2013 · 29,225 citations

Bookmark

View Full Paper